Alembic Pharmaceuticals Gains USFDA Nod for Generic Tretinoin Cream

Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tretinoin Cream USP, 0.025%. The approval allows the Indian pharmaceutical company to launch a generic version of the treatment, which is widely prescribed for the management of acne vulgaris.

The newly approved product is therapeutically equivalent to the reference listed drug (RLD), Retin-A Cream 0.025%, marketed in the United States by Bausch Health US, LLC. The expansion into the generic acne treatment segment represents a strategic move for Alembic as it continues to grow its presence in the U.S. generic drug market.

Tapping into a $94 Million Market

Data from market intelligence firm IQVIA indicates that the U.S. market for Tretinoin Cream USP, 0.025%, was valued at approximately $94 million for the 12-month period ending in June 2025. With this latest regulatory milestone, Alembic Pharmaceuticals aims to capture a portion of this significant market share by offering a cost-effective generic alternative to healthcare providers and patients.

Alembic’s regulatory success continues a string of positive developments for the company. Following this latest approval, the firm’s cumulative total of ANDA approvals stands at 224, consisting of 202 final approvals and 22 tentative approvals from the U.S. health regulator.

Commitment to Dermatology and Generic Healthcare

Tretinoin cream, a topical retinoid, is a staple in dermatological care, commonly used to treat acne vulgaris by promoting skin cell turnover. Alembic Pharmaceuticals, which has been operational since 1907, maintains a strong focus on research and development, particularly in the branded and generic formulations space.

"The company’s state-of-the-art research and manufacturing facilities are accredited by regulatory authorities of several developed nations, including the USFDA," the company stated in a recent regulatory filing. This latest approval reinforces the company's capability to navigate complex regulatory landscapes and bring high-quality generic medications to global markets.

Official Sources

• Alembic Pharmaceuticals: Official Regulatory Filings and Press Releases

• U.S. Food and Drug Administration (FDA): Orange Book Data

• BSE India (Bombay Stock Exchange) Corporate Announcements

Quote Section

"According to official statements from Alembic Pharmaceuticals, the approval of the ANDA for Tretinoin Cream USP, 0.025% marks a significant addition to the company's U.S. generics portfolio and aligns with its objective to provide accessible healthcare solutions to patients globally."

Why It Matters

For patients in the United States, the entry of generic equivalents often leads to increased availability and reduced out-of-pocket costs for essential skincare treatments. For Alembic Pharmaceuticals, the approval underscores the company's ongoing success in international markets, providing a reliable revenue stream in the high-demand dermatology sector.

Key Facts at a Glance

• Approved Medication: Tretinoin Cream USP, 0.025%.

• Indication: Topical treatment of acne vulgaris.

• Market Opportunity: Estimated $94 million U.S. market size (as of June 2025).

• Reference Drug: Therapeutically equivalent to Bausch Health’s Retin-A Cream.

• Portfolio Strength: Marks Alembic's 202nd final USFDA ANDA approval.

FAQ

1. What is Tretinoin Cream used for? Tretinoin cream is a topical retinoid used primarily for the treatment of acne vulgaris, helping to reduce the number and severity of acne lesions.

2. Is this a brand-name drug? No, this is a generic version of the reference listed drug, Retin-A Cream, which is manufactured by Bausch Health US, LLC.

3. When will this product be available in U.S. pharmacies? While FDA approval is a critical step, specific commercial launch timelines are determined by the company's internal supply chain and distribution strategies.

Source: Alembic Pharmaceuticals, FDA, BSE India